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Abstract 
Weighted burden pathway analysis was applied to whole exome sequence data for 2045 
schizophrenic subjects and 2045 controls. Overall, there was a statistically significant excess 
of pathways with more rare, functional variants in cases than controls. Among the highest 
ranked were pathways relating to histone modification, as well neuron differentiation and 
membrane and vesicle function. This bolsters the evidence from previous studies that 
histone modification pathways may be important in the aetiology of schizophrenia. 
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Introduction 
A previous pathway analysis based on SNP results from GWAS data for schizophrenia, 
major depression and bipolar disorder implicated neuronal, immune and histone pathways, 
with histone methylation being the most strongly associated (The Network and Pathway 
Analysis Subgroup of the Psychiatric Genomics Consortium 2015). In a study of de novo 
variants in schizophrenia, two unrelated cases were found to have de novo loss of function 
variants in SETD1A, which encodes for a component of a histone methyltransferase 
complex, and a subsequent study has discovered further loss of function variants in this 
gene in subjects with schizophrenia and in subjects with intellectual disability (Takata, Xu et 
al. 2014; Singh, Kurki et al. 2016). 
In previously reported studies, Swedish subjects with schizophrenia and matched controls 
underwent whole exome sequencing but gene-wise burden tests did not produce any 
individually significant results for dominant or recessive effects (Purcell, Moran et al. 2014) 
(Curtis 2015). However, it was reported that there was an excess of variants in particular 
gene sets including voltage-gated calcium ion channels and the signalling complex formed 
by the activity-regulated cytoskeleton-associated scaffold protein (ARC) of the postsynaptic 
density (Purcell, Moran et al. 2014). 
The present study aimed to examine a comprehensive set of pathways with no a priori 
selection in order to determine if  any appeared to be enriched for rare, putatively functional 
variants among cases as opposed to controls. 
 
Methods 
The data analysed consisted of whole exome sequence data downloaded from dbGaP for 
2545 controls and 2545 cases of schizophrenia from Sweden. This dataset is almost the 
same as that used previously except that the original study did not include a small number of 
cases and controls so that the published totals differ slightly (Purcell, Moran et al. 2014). 
Version hg19 of the reference human genome sequence and RefSeq genes were used to 
select variants on a gene-wise basis and to annotate them.  
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A number of quality control processes were applied to exclude some variants from analysis. 
As described originally (Purcell, Moran et al. 2014), genotypes were called with the 
Picard/BWA/GATK pipeline which assigns a "PASS" to variants called with a high degree of 
confidence and which also assigns a genotype quality score to each genotype at an 
individual level. Variants were excluded if they did not have a PASS in the information field  
and individual genotype calls were excluded if they had a quality score less than 30. 
Preliminary analyses revealed that even when these measures had been applied some 
variants would throw up obviously erroneous results such as having a marked excess of 
homozygotes in both cases and controls or having implausibly large differences in allele 
frequency between cases and controls. Such spurious results tended to occur for indels and 
for variants for which a substantial proportion of genotype calls did not have a high quality 
score (even after the low scoring genotypes were excluded). Hence it was decided that indel 
calls were unreliable and attention was restricted to substitutions, to which the following 
additional quality control measures were applied: variants were excluded if there were more 
than 100 genotypes missing  or of low quality in either cohort or if the heterozygote count 
was smaller than both homozygote counts in both cohorts.  
 
Weighted burden analyses were carried out as previously described using the 
SCOREASSOC program (Curtis 2012) (Curtis and UK10K Consortium 2015). Each variant is 
assigned a weight determined by its rarity and by its predicted functional effect. The rarity 
weight is allocated using a parabolic function such that very rare variants have a weight of 
10 compared with a weight of 1 for common variants with minor allele frequency (MAF) 
equal to 0.5. Functional weights are assigned arbitrarily so that variant types deemed more 
likely to have a functional effect are assigned higher weights in an approach similar to that 
recently suggested for dealing with de novo mutations (Jiang, Han et al. 2015). Stop gain 
mutations are allocated a weight of 20. Non-synonymous and Kozak sequence variants are 
assigned a weight of 10. Stop loss, 3' and 5' UTR and splice site variants are assigned a 
weight of 5. Synonymous and intronic variants are assigned a weight of 3. Intergenic 
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variants are assigned a weight of 1. The weight according to rarity is then multiplied by the 
weight according to function, so that for example an extremely rare stop variant would be 
assigned an overall weight of 200 while a common intergenic variant would be assigned an 
overall weight of 1. The previously reported gene-based analyses were applied to two sets of 
variants, either all variants or else only nonsynonymous or stop variants with MAF<0.1. In 
order to minimise multiple testing issues, for the pathway analysis reported here only the 
latter set of variants was used. Among these, the stop variants would be weighted more 
highly than nonsynonymous variants and very rare variants would be weighted more highly 
than those which were less rare. 
 
Variants for each gene were input into SCOREASSOC, which sums the overall weights for 
the variants possessed by each subject to produce a score for that subject. It then performs 
a t test comparing scores for cases and controls to test whether cases tend to have an 
excess of rare, functional variants. The result of this weighted burden test is summarised as 
a signed log p (SLP), which is the logarithm base 10 of the two-tailed p value, given a 
positive sign if the mean score is higher for cases than controls.  
 
In order to carry out pathway analysis, the 1454 "all GO gene sets, gene symbols" pathways 
were downloaded from the Molecular Signatures Database at 
http://www.broadinstitute.org/gsea/msigdb/collections.jsp (Subramanian, Tamayo et al. 
2005). For each pathway, the scores for each constituent gene of the pathway as output by 
SCOREASSOC were summed to produce a total score for each subject for that pathway. 
Then a t test was performed to compare total scores between cases and controls and the 
results expressed an SLP. Although the scores were obtained on a gene-wise basis, this 
approach to pathway analysis, which was proposed in the original SCOREASSOC paper 
(Curtis 2012), actually considers all variants within the pathway simultaneously rather than 
using summary statistics from genes and then combining them. This means that the test is 
not expected to be biased by genes with different sizes or having different numbers of 
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variants and overall the test statistic should follow the asymptotic distribution if the null 
hypothesis is true and there is no difference in variant burden for the pathway between 
cases and controls. On the other hand, the pathways are not independent of each other as 
the same gene can appear in more than one. Thus, although one can specify the probability 
for the SLP for a particular pathway to exceed a given threshold one cannot state the 
probability for a certain number of the 1454 pathways to exceed a threshold. The fact that 
the pathways are not independent means that a Bonferroni correction for a single p value 
might be conservative whereas using a binomial distribution to assess the significance of an 
observed number of pathways exceeding a threshold might be anti-conservative. 
 
In order to address this issue, permutation testing was used. An SLP was obtained for each 
pathway and then an additional 9,999 simulated datasets were obtained by permuting the 
subject phenotypes and all the SLPs for all pathways were recalculated. Thus, if for example 
17 pathways produced an SLP over 2 in the real dataset and 49 of the simulated datasets 
also yielded 17 or more pathways with an SLP over 2 then one could declare that the real 
dataset was in the highest 50 out of 10,000 and one could declare that there was an excess 
of pathways with SLP over 2 with an empirical p value of 50/1000=0.005 (North, Curtis et al. 
2002). This approach provided an experiment-wide statistical significance for an excess of 
pathways in which rare, functional variants were commoner among cases than controls. 
Carrying out these simulations also confirmed that for each individual pathway the 
asymptotic p values obtained corresponded very closely with empirical p value for that 
pathway. 
 
Care was taken to minimise problems related to multiple testing, so that only a single set of 
pathway definitions was used and only a single method of analysis was applied. 
 
Results 
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As shown in Figure 1, a Q:Q plot of the SLPs revealed that pathways in which the numbers 
of variants were higher in controls than in cases, i.e. those with negative SLPs, exactly 
followed the expected distribution. However for the pathways with positive SLPs the gradient 
was steeper, suggesting an excess of variants among cases in a large number of pathways.  
 
Figure 1 
Q:Q plots for SLPs obtained from the pathway analyses compared to values expected under 
null hypothesis. Positive SLPs indicate an excess of rare, functional variants in SZ cases, 
negative SLPs indicate an excess in controls. 
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The 50 pathways with the highest SLPs are shown in Table 1, along with contributing genes 
having an SLP>1.3 (equivalent to gene-wise p<0.05). 2 pathways have SLP higher than 4, 3 
have SLP higher than 3 and 22 have SLP higher than 2. The permutation testing revealed 
the expected values for these figures to be 0.07, 0.7 and 7.3 with experiment-wide statistical 
significance of 0.014, 0.16 and 0.03 respectively. Thus, there is overall a significant excess 
of pathways with high SLPs and it is likely that at least some of the higher ranked pathways 
indicate a true biological effect.  
 
Table 1 
Table showing the most 50 most highly ranked GO pathways out of 1454 tested. For each 
pathway is shown the signed log10 p value (SLP) for a weighted burden test which tests for 
an excess of rare, functional variants in 2045 schizophrenia cases versus 2045 controls. 
Also shown is a list of all contributing genes individually having SLP>1.3, equivalent to a 
gene-wise p value of 0.05. 
Pathway name SLP Number 
of genes 
Contributing gene (SLP) for genes 
with gene-wiseSLP>1.3 
CELL CYCLE ARREST  4.26 57  KAT2B (2.41), PPP2R3B (2.16), 
EIF4G2 (1.5), TBRG4 (1.35), 
TP53 (1.6) 
HETEROCYCLE METABOLIC 
PROCESS 
4.12 27  COX10 (2.98), ALDH1L1 (1.35) 
COVALENT CHROMATIN 
MODIFICATION 
3.14 25  NSD1 (1.86), HELLS (1.88) 
HISTONE MODIFICATION 2.94 24  NSD1 (1.86) 
MEMBRANE ORGANIZATION 
AND BIOGENESIS 
2.92 135  SNAP23 (1.74), TP53 (1.6), 
NECAP2 (1.37), ASGR1 (1.89), 
MSR1 (1.98), AGRN (1.41), SNX1 
(2.25), PICALM (1.52) 
NEGATIVE REGULATION OF 
TRANSCRIPTION FROM RNA 
POLYMERASE II PROMOTER 
2.92 84  DNMT1 (2.42), PHF21A (1.42), 
JAZF1 (1.84), VHL (1.31), NSD1 
(1.86), PAWR (1.54) 
NEGATIVE REGULATION OF 
CELL CYCLE 
2.76 79  KAT2B (2.41), PPP2R3B (2.16), 
EIF4G2 (1.5), TBRG4 (1.35), 
TP53 (1.6) 
REGULATION OF SECRETION 2.73 40  NLRP12 (1.55), SRGN (1.48), 
SNCAIP (1.36) 
PROTEIN SERINE THREONINE 
PHOSPHATASE COMPLEX 
2.64 10  PPP2R3B (2.16) 
PROTEIN N TERMINUS BINDING 2.62 38  NCOA3 (2.19), TP53 (1.6) 
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NEGATIVE REGULATION OF 
RNA METABOLIC PROCESS 
2.59 132  PHF21A (1.42), VHL (1.31), 
NSD1 (1.86), PAWR (1.54), 
DNMT1 (2.42), JAZF1 (1.84), 
HELLS (1.88), ZHX3 (1.76) 
NEGATIVE REGULATION OF 
TRANSCRIPTION DNA 
DEPENDENT 
2.58 130  PHF21A (1.42), VHL (1.31), 
NSD1 (1.86), PAWR (1.54), 
DNMT1 (2.42), JAZF1 (1.84), 
HELLS (1.88), ZHX3 (1.76) 
NEGATIVE REGULATION OF 
BIOLOGICAL PROCESS 
2.57 677  KAT2B (2.41), ERCC1 (1.5), 
EIF4G2 (1.5), NOL3 (1.88), 
DNMT1 (2.42), CFLAR (1.46), 
SRGN (1.48), ELK3 (1.73), EMP3 
(1.83), PTHLH (1.34), CBX4 
(1.44), PTCH1 (1.35), PHF21A 
(1.42), BCL3 (1.41), SEMA4D 
(1.34), JAZF1 (1.84), TBRG4 
(1.35), VHL (1.31), GPNMB (1.33), 
WARS (3.48), PAWR (1.54), 
FABP6 (1.46), HELLS (1.88), 
NLRP12 (1.55), TMPRSS6 (1.31), 
RTKN (2.63), NSD1 (1.86), TP53 
(1.6), PPP2R3B (2.16), ADAMTS1 
(1.7), ZHX3 (1.76) 
HELICASE ACTIVITY 2.51 51  CHD1 (2.01), RUVBL1 (1.5), 
DDX20 (2.7), DDX18 (2.02) 
REGIONALIZATION 2.5 15  PTCH1 (1.35), T (1.47) 
BIOGENIC AMINE METABOLIC 
PROCESS 
2.46 17  SNCAIP (1.36) 
FEEDING BEHAVIOR 2.45 24  FYN (2.52) 
CLATHRIN COATED VESICLE 2.41 37  NECAP2 (1.37) 
ATP DEPENDENT HELICASE 
ACTIVITY 
2.4 27  DDX20 (2.7), CHD1 (2.01), 
DDX18 (2.02) 
PIGMENT METABOLIC 
PROCESS 
2.32 18  COX10 (2.98) 
RECEPTOR MEDIATED 
ENDOCYTOSIS 
2.29 33  PICALM (1.52), ASGR1 (1.89), 
MSR1 (1.98) 
PROTEIN PHOSPHATASE TYPE 
2A REGULATOR ACTIVITY 
2.28 14  PPP2R3B (2.16) 
HEME METABOLIC PROCESS 2.25 11  COX10 (2.98) 
NEGATIVE REGULATION OF 
CELLULAR PROCESS 
2.23 646  KAT2B (2.41), ERCC1 (1.5), 
EIF4G2 (1.5), NOL3 (1.88), 
DNMT1 (2.42), CFLAR (1.46), 
ELK3 (1.73), EMP3 (1.83), PTHLH 
(1.34), CBX4 (1.44), PHF21A 
(1.42), BCL3 (1.41), SEMA4D 
(1.34), JAZF1 (1.84), TBRG4 
(1.35), VHL (1.31), GPNMB (1.33), 
WARS (3.48), PAWR (1.54), 
FABP6 (1.46), HELLS (1.88), 
NLRP12 (1.55), RTKN (2.63), 
NSD1 (1.86), TP53 (1.6), 
PPP2R3B (2.16), ADAMTS1 (1.7), 
ZHX3 (1.76) 
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PIGMENT BIOSYNTHETIC 
PROCESS 
2.21 17  COX10 (2.98) 
STEROID HORMONE 
RECEPTOR BINDING 
2.19 10  NSD1 (1.86) 
CHROMATIN MODIFICATION 2.17 55  HELLS (1.88), NSD1 (1.86) 
HEME BIOSYNTHETIC 
PROCESS 
2.13 10  COX10 (2.98) 
RESPONSE TO OTHER 
ORGANISM 
2.07 83  BCL3 (1.41), FOSL1 (1.31) 
GROWTH FACTOR ACTIVITY 2.05 55  
VITAMIN TRANSPORT 2.02 13  SLC19A1 (1.59), CUBN (2.24) 
NEURON DIFFERENTIATION 2.02 76  AGRN (1.41), FARP2 (1.8), CDK5 
(1.49), MDGA2 (1.47) 
RNA HELICASE ACTIVITY 1.99 24  DDX20 (2.7), DDX18 (2.02) 
NEGATIVE REGULATION OF 
TRANSLATION 
1.99 23  BCL3 (1.41), NLRP12 (1.55) 
COFACTOR BIOSYNTHETIC 
PROCESS 
1.94 21  COX10 (2.98) 
HORMONE RECEPTOR BINDING 1.89 83  NSD1 (1.86), MED14 (1.34) 
GENERATION OF NEURONS 1.89 29  AGRN (1.41), FARP2 (1.8), CDK5 
(1.49), MDGA2 (1.47) 
PHOSPHATASE REGULATOR 
ACTIVITY 
1.87 16  PPP2R3B (2.16) 
OXIDOREDUCTASE ACTIVITY 
ACTING ON THE ALDEHYDE OR 
OXO GROUP OF DONORS NAD 
OR NADP AS ACCEPTOR 
1.87 26  ALDH4A1 (1.99) 
NEUROPEPTIDE BINDING 1.86 23  NMBR (1.6) 
NUCLEAR HORMONE 
RECEPTOR BINDING 
1.85 28  NSD1 (1.86), MED14 (1.34) 
RESPONSE TO NUTRIENT 
LEVELS 
1.84 47  TP53 (1.6) 
COATED VESICLE 1.84 29  COPE (1.41), NECAP2 (1.37) 
PROTEIN PHOSPHATASE 
BINDING 
1.83 10  
RESPONSE TO VIRUS 1.82 50  BCL3 (1.41), FOSL1 (1.31) 
COFACTOR METABOLIC 
PROCESS 
1.81 54  ACOT12 (1.31), COX10 (2.98), 
ALDH1L1 (1.35) 
AMINO ACID DERIVATIVE 
METABOLIC PROCESS 
1.78 24  SNCAIP (1.36) 
NUCLEAR CHROMATIN 1.78 14  H2AFY2 (1.62) 
MORPHOGENESIS OF AN 
EPITHELIUM 
1.77 16  KRT3 (3.52) 
HISTONE 
METHYLTRANSFERASE 
ACTIVITY 
1.74 11  NSD1 (1.86), SUZ12 (1.59) 
 
For each pathway are listed any genes which individually produced an SLP>1.3. Of course, 
other genes will have contributed to the overall score for the pathway and the results do not 
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allow for certainty as whether any individual gene or pathway is definitely implicated. It 
should also be noted that some of these genes are shared between pathways, for example 
NSD1, HELLS, PHF21A and PAWR. This interdependency of pathways was accounted for 
in the permutation testing and does not invalidate the reported p values.  
 
Discussion 
This study analysed a comprehensive set of pathways with no a priori attempt to focus on 
those which might be assumed to have increased relevance to schizophrenia aetiology. The 
method used is not expected to be biased by factors such as gene size or variant density 
and the conformation with the asymptotic distribution and the results of permutation analysis 
support the validity of the approach. Rather than dichotomising variants simply into those 
which are used and those which are discarded, the approach allows a broader range of 
variants to be included and then assigns them differential weights. 
 
It is of note that a number of the highly ranked pathways are related to histone modification 
and transcription regulation. Others involve vesicle function, endocytosis and neuronal 
generation and differentiation. Although one case and no control were noted to have a stop 
mutation in SETD1A, this gene was not included in any of the pathway definitions and so did 
not contribute to these results. Thus this pathway analysis can be considered as 
independent of other reports suggesting that histone modification processes may have an 
important role in the aetiology of schizophrenia.  
 
Intriguingly, a recent report demonstrates that histone turnover has a critical role in a variety 
of neuronal functions, including both synaptic development and activity dependent 
transcription (Maze, Wenderski et al.). This suggests the possibility that disruption of normal 
histone processing might plausibly give rise to neuropsychiatric syndromes, including 
schizophrenia. Given the cumulative weight of evidence now emerging from different 
sources, it seems that further research could usefully focus in this area. 
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Table 1 
Table showing the most 50 most highly ranked GO pathways out of 1454 tested. For each 
pathway is shown the signed log10 p value (SLP) for a weighted burden test which tests for 
an excess of rare, functional variants in 2045 schizophrenia cases versus 2045 controls. 
Also shown is a list of all contributing genes individually having SLP>1.3, equivalent to a 
gene-wise p value of 0.05. 
Pathway name SLP Number 
of genes 
Contributing gene (SLP) for genes 
with gene-wiseSLP>1.3 
CELL CYCLE ARREST  4.26 57  KAT2B (2.41), PPP2R3B (2.16), 
EIF4G2 (1.5), TBRG4 (1.35), 
TP53 (1.6) 
HETEROCYCLE METABOLIC 
PROCESS 
4.12 27  COX10 (2.98), ALDH1L1 (1.35) 
COVALENT CHROMATIN 
MODIFICATION 
3.14 25  NSD1 (1.86), HELLS (1.88) 
HISTONE MODIFICATION 2.94 24  NSD1 (1.86) 
MEMBRANE ORGANIZATION 
AND BIOGENESIS 
2.92 135  SNAP23 (1.74), TP53 (1.6), 
NECAP2 (1.37), ASGR1 (1.89), 
MSR1 (1.98), AGRN (1.41), SNX1 
(2.25), PICALM (1.52) 
NEGATIVE REGULATION OF 
TRANSCRIPTION FROM RNA 
POLYMERASE II PROMOTER 
2.92 84  DNMT1 (2.42), PHF21A (1.42), 
JAZF1 (1.84), VHL (1.31), NSD1 
(1.86), PAWR (1.54) 
NEGATIVE REGULATION OF 
CELL CYCLE 
2.76 79  KAT2B (2.41), PPP2R3B (2.16), 
EIF4G2 (1.5), TBRG4 (1.35), 
TP53 (1.6) 
REGULATION OF SECRETION 2.73 40  NLRP12 (1.55), SRGN (1.48), 
SNCAIP (1.36) 
PROTEIN SERINE THREONINE 
PHOSPHATASE COMPLEX 
2.64 10  PPP2R3B (2.16) 
PROTEIN N TERMINUS BINDING 2.62 38  NCOA3 (2.19), TP53 (1.6) 
NEGATIVE REGULATION OF 
RNA METABOLIC PROCESS 
2.59 132  PHF21A (1.42), VHL (1.31), 
NSD1 (1.86), PAWR (1.54), 
DNMT1 (2.42), JAZF1 (1.84), 
HELLS (1.88), ZHX3 (1.76) 
NEGATIVE REGULATION OF 
TRANSCRIPTION DNA 
DEPENDENT 
2.58 130  PHF21A (1.42), VHL (1.31), 
NSD1 (1.86), PAWR (1.54), 
DNMT1 (2.42), JAZF1 (1.84), 
HELLS (1.88), ZHX3 (1.76) 
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NEGATIVE REGULATION OF 
BIOLOGICAL PROCESS 
2.57 677  KAT2B (2.41), ERCC1 (1.5), 
EIF4G2 (1.5), NOL3 (1.88), 
DNMT1 (2.42), CFLAR (1.46), 
SRGN (1.48), ELK3 (1.73), EMP3 
(1.83), PTHLH (1.34), CBX4 
(1.44), PTCH1 (1.35), PHF21A 
(1.42), BCL3 (1.41), SEMA4D 
(1.34), JAZF1 (1.84), TBRG4 
(1.35), VHL (1.31), GPNMB (1.33), 
WARS (3.48), PAWR (1.54), 
FABP6 (1.46), HELLS (1.88), 
NLRP12 (1.55), TMPRSS6 (1.31), 
RTKN (2.63), NSD1 (1.86), TP53 
(1.6), PPP2R3B (2.16), ADAMTS1 
(1.7), ZHX3 (1.76) 
HELICASE ACTIVITY 2.51 51  CHD1 (2.01), RUVBL1 (1.5), 
DDX20 (2.7), DDX18 (2.02) 
REGIONALIZATION 2.5 15  PTCH1 (1.35), T (1.47) 
BIOGENIC AMINE METABOLIC 
PROCESS 
2.46 17  SNCAIP (1.36) 
FEEDING BEHAVIOR 2.45 24  FYN (2.52) 
CLATHRIN COATED VESICLE 2.41 37  NECAP2 (1.37) 
ATP DEPENDENT HELICASE 
ACTIVITY 
2.4 27  DDX20 (2.7), CHD1 (2.01), 
DDX18 (2.02) 
PIGMENT METABOLIC 
PROCESS 
2.32 18  COX10 (2.98) 
RECEPTOR MEDIATED 
ENDOCYTOSIS 
2.29 33  PICALM (1.52), ASGR1 (1.89), 
MSR1 (1.98) 
PROTEIN PHOSPHATASE TYPE 
2A REGULATOR ACTIVITY 
2.28 14  PPP2R3B (2.16) 
HEME METABOLIC PROCESS 2.25 11  COX10 (2.98) 
NEGATIVE REGULATION OF 
CELLULAR PROCESS 
2.23 646  KAT2B (2.41), ERCC1 (1.5), 
EIF4G2 (1.5), NOL3 (1.88), 
DNMT1 (2.42), CFLAR (1.46), 
ELK3 (1.73), EMP3 (1.83), PTHLH 
(1.34), CBX4 (1.44), PHF21A 
(1.42), BCL3 (1.41), SEMA4D 
(1.34), JAZF1 (1.84), TBRG4 
(1.35), VHL (1.31), GPNMB (1.33), 
WARS (3.48), PAWR (1.54), 
FABP6 (1.46), HELLS (1.88), 
NLRP12 (1.55), RTKN (2.63), 
NSD1 (1.86), TP53 (1.6), 
PPP2R3B (2.16), ADAMTS1 (1.7), 
ZHX3 (1.76) 
PIGMENT BIOSYNTHETIC 
PROCESS 
2.21 17  COX10 (2.98) 
STEROID HORMONE 
RECEPTOR BINDING 
2.19 10  NSD1 (1.86) 
CHROMATIN MODIFICATION 2.17 55  HELLS (1.88), NSD1 (1.86) 
HEME BIOSYNTHETIC 
PROCESS 
2.13 10  COX10 (2.98) 
RESPONSE TO OTHER 2.07 83  BCL3 (1.41), FOSL1 (1.31) 
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ORGANISM 
GROWTH FACTOR ACTIVITY 2.05 55  
VITAMIN TRANSPORT 2.02 13  SLC19A1 (1.59), CUBN (2.24) 
NEURON DIFFERENTIATION 2.02 76  AGRN (1.41), FARP2 (1.8), CDK5 
(1.49), MDGA2 (1.47) 
RNA HELICASE ACTIVITY 1.99 24  DDX20 (2.7), DDX18 (2.02) 
NEGATIVE REGULATION OF 
TRANSLATION 
1.99 23  BCL3 (1.41), NLRP12 (1.55) 
COFACTOR BIOSYNTHETIC 
PROCESS 
1.94 21  COX10 (2.98) 
HORMONE RECEPTOR BINDING 1.89 83  NSD1 (1.86), MED14 (1.34) 
GENERATION OF NEURONS 1.89 29  AGRN (1.41), FARP2 (1.8), CDK5 
(1.49), MDGA2 (1.47) 
PHOSPHATASE REGULATOR 
ACTIVITY 
1.87 16  PPP2R3B (2.16) 
OXIDOREDUCTASE ACTIVITY 
ACTING ON THE ALDEHYDE OR 
OXO GROUP OF DONORS NAD 
OR NADP AS ACCEPTOR 
1.87 26  ALDH4A1 (1.99) 
NEUROPEPTIDE BINDING 1.86 23  NMBR (1.6) 
NUCLEAR HORMONE 
RECEPTOR BINDING 
1.85 28  NSD1 (1.86), MED14 (1.34) 
RESPONSE TO NUTRIENT 
LEVELS 
1.84 47  TP53 (1.6) 
COATED VESICLE 1.84 29  COPE (1.41), NECAP2 (1.37) 
PROTEIN PHOSPHATASE 
BINDING 
1.83 10  
RESPONSE TO VIRUS 1.82 50  BCL3 (1.41), FOSL1 (1.31) 
COFACTOR METABOLIC 
PROCESS 
1.81 54  ACOT12 (1.31), COX10 (2.98), 
ALDH1L1 (1.35) 
AMINO ACID DERIVATIVE 
METABOLIC PROCESS 
1.78 24  SNCAIP (1.36) 
NUCLEAR CHROMATIN 1.78 14  H2AFY2 (1.62) 
MORPHOGENESIS OF AN 
EPITHELIUM 
1.77 16  KRT3 (3.52) 
HISTONE 
METHYLTRANSFERASE 
ACTIVITY 
1.74 11  NSD1 (1.86), SUZ12 (1.59) 
 
